Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA Approves Polymedco’s OC-Sensor Diana
The company said that the new OC-Sensor Diana system measures 280 FIT samples per hour and ensures that quality data is consistently collected. In addition, its compact design
The company said that the new OC-Sensor Diana system measures 280 FIT samples per hour and ensures that quality data is consistently collected. In addition, its compact design
Auxilium has established a distribution network that will allow health care providers to access Xiaflex through specialty distributors and specialty pharmacies or in the institutional setting after they
Roche reported an operating profit of CHF15.012bn for the FY 2009, compared to CHF13.896bn for the FY 2008, an increase of 14%. The net income of the company
The primary efficacy endpoint for Hokusai VTE is the recurrence of symptomatic VTE. The primary safety assessment of the trial is the incidence of major and clinically relevant
The company said that the newly patented method extends the ability of the Entelos Metabolism PhysioLab platform to explore, simulate, and predict differences in fuel utilisation between patients,
The MermaiHD study met the primary endpoint to show an effect on voluntary motor function. In addition, data from the 437 huntington patients, who participated in the study
As per the agreement, the total milestone payments could reach GBP207m in the event of launch in multiple indications. Apeiron will receive an up-front payment of GBP11m in
The compound was originally developed by Kissei Pharmaceutical in Japan and was obtained under license by Recordati for the whole of Europe and 18 countries in the Middle
The Elixia range of six products, including an Anti-oxidant Serum and a Multi V Moisturiser, uses the Phosphagenics’ patented TPM (Targeted Penetration Matrix) delivery technology to deliver more
Rik Deitsch, chairman and CEO of Nutra Pharma, said: “We were extremely pleased with our fourth quarter Cobroxin sales, especially given its initial limited retail availability. With the